Table 2. Primary endpoints and Kaplan-Meier estimates by treatment groups.
| Outcomes | Overall study population, n=211 | Group A: UR+AT, n=140 | Group B: NAT+R+AT, n=71 | P value |
|---|---|---|---|---|
| LRFS-event, n (%) | 15 (7.1) | 10 (7.1) | 5 (7.0) | 0.979 |
| DRFS-event, n (%) | 23 (10.9) | 20 (14.3) | 3 (4.2) | 0.037 |
| OS-event, n (%) | 9 (4.3) | 6 (4.3) | 3 (4.2) | 0.984 |
| 5-year LRFS | 90.70% | 90.30% | 92.50% | 0.42 |
| 5-year DRFS | 85.60% | 84.10% | 89.50% | 0.189 |
| 5-year OS | 92.50% | 93.80% | 87.50% | 0.783 |
NAT, neoadjuvant therapy with imatinib; R, resection; AT, adjuvant therapy with imatinib; UR, upfront resection; LRFS, local recurrence-free survival; DRFS, distance recurrence-free survival; OS, overall survival.